Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for December 2012
December 1, 2012
December 3, 2012
- Merck Initiates Phase II/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer's Disease
- Sucampo Falls As FDA Extends Amitiza Review
- Endo Health Solutions Sues FDA to Protect Consumers from Non-Tamper Resistant Oxymorphone
- Biogen Comes Back Strong
- Teva Pharma 2013 Forecast Misses Expectations
- Families Carry A Major Burden of the Diabetes Pandemic, According to New Results From Global Study
- Pharmaceutical Giant Sanofi Pasteur Seeks to Muzzle CREW from Speaking Out
- New Study on Physician Online Behaviors Shows Health Care Professional Sites Reach 4 out of 5 Physicians, While Electronic Medical Records Show Highest Engagement
- PDL BioPharma Announces Resignation of Chief Financial Officer
- ImmunoCellular Therapeutics Appoints Andrew Gengos as Chief Executive Officer
December 4, 2012
- Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel
- Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro
- Decision Resources Group Acquires Abacus International
- Immunocellular Therapeutics Names Gengos As CEO
- Protein Sciences Invests in Flu Vaccine Facility
- AstraZeneca Makes Major Commitment to Help Patients with Acute Coronary Syndrome Have Brilinta (ticagrelor) Available in Their Local Communities
- Wilex AG Announces Restructuring
December 5, 2012
- FDA Drug Safety Communication: Updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products
- E. German Secret Drug Tests Reported
- Geron Discontinues GRN1005 and Restructures to Focus on Imetelstat Development in Hematologic Malignancies and Solid Tumors with Short Telomeres
- Strides Arcolab and Lilly Enter Strategic Partnership to Deliver High-Quality, Branded Generic Cancer Medicines for Emerging Markets
- CSL Renames its Australian Operations
- Chelsea Therapeutics Skids on Northera Study Data
December 6, 2012
- Elan Announces Record Date in Respect of Proposed Demerger
- Boehringer Ingelheim and Apexigen Sign Manufacturing Agreement for Process Development and Early Stage Clinical Supply
- Mylan Launches Generic Version of Atacand HCT
- NICE Draft Guidance Recommends Wider Use of Abatacept in Treating Rheumatoid Arthritis
- Fostering Access to Innovative Medicines in Indonesia
- Judgment in Case C-457/10 P AstraZeneca v Commission
- First Suit Against Nobel Prize Organization Citing Defamation And Unfair Competition Practices Is Filed
December 7, 2012
- NICE Consults on Preliminary Recommendations for a New Kidney Cancer Drug
- FDA Drug Safety Communication: Important Change to Heparin Container Labels to Clearly State the Total Drug Strength
- BioCryst Pharmaceuticals Announces Focused Corporate Strategy and Restructuring
- Qualitest Issues Voluntary, Nationwide Recall of 101 Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
- UT MD Anderson, GlaxoSmithKline To Collaborate On New Approach To Cancer Immune Therapy; Success Could Earn Cancer Center $335 Million Plus Royalties
- Bayer Consumer Care Voluntarily Recalls 56 Lots of Bronkaid Caplets Dual Action Formula due to Product Labeling Error
December 10, 2012
- Nuron Biotech Acquires Commercial, Preventive Vaccine Meningitec from Pfizer
- WIN Consortium and Pfizer Collaborate to Advance Personalized Cancer Care
- Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
- Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
December 11, 2012
- Sucampo Receives $15 Million Milestone Payment from Abbott on First Sale of AMITIZA (lubiprostone) in Japan
- Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
- Teva and Xenon Announce Teva's World Wide License of Xenon's Pain Drug XEN402
- Eisai Granted Additional Six Month U.S. Marketing Exclusivity For Aciphex (Rabeprazole Sodium)
- WebMD Streamlines Business and Expects to Reduce Annualized Operating Expenses by $45 Million
- Quit.com Launches as Comprehensive New Resource to Help Smokers Quit and Stay Smoke-Free
December 12, 2012
- Boehringer Ingelheim Discontinues Phase II Trial in Patients with Artificial Heart Valves
- FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease
- Lilly Provides Update on Next Steps for Solanezumab
- The Medicines Company Agrees to Acquire Incline Therapeutics, Inc.
- Teva Pharmaceuticals to Narrow Focus on Drugs, Trim Costs
- The Medicines Company and Bristol-Myers Squibb Agree to Global Alliance for Recothrom
- iCell Neurons Enable Alzheimer's Disease Modeling and Demonstrate Potential Use in High Throughput Screening at GlaxoSmithKline
- Biogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle Park Facilities
- Gilead Sciences to Acquire YM BioSciences
December 13, 2012
- Chantix (Varenicline): Safety Communication - Updated Safety Review On The Risk of Cardiovascular Adverse Events
- FDA Drug Safety Communication: Safety Review Update of Chantix (varenicline) and Risk of Cardiovascular Adverse Events
- Endo Health Solutions Announces CEO Transition Plan
- Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
December 14, 2012
- Astellas Announces Recruitment Completion of Phase 3 Pivotal Study of Isavuconazole, an Agent for the Potential Primary Treatment of Invasive and Life-threatening Fungal Infections
- Dr. Reddy's Launches the Recommended Public Cash Offer for All the Issued and Outstanding Ordinary Shares of OctoPlus N.V.
- Committee for Medicinal Products for Human Use (CHMP)Summary of opinion1 (post authorisation) Ixiaro Japanese encephalitis vaccine (inactivated, adsorbed)
- Questions and answers on the review of medicines for which studies have been conducted at Texas-based Cetero Research facility
December 17, 2012
- Hospira Issues Voluntary Nationwide Recall of Three Lots of Carboplatin Injection Due to Visible Particulate Matter
- Patheon Completes Acquisition of Banner Pharmacaps
- Evotec Announces NMDA Antagonist License Agreement
- Phenex Enters Into a Research Collaboration and License Agreement with Janssen for Autoimmune and Chronic Inflammatory Disorders
- Enzon to Review Asset Sales, Sale of the Company
- CRESTOR US patent upheld by Court of Appeals for the Federal Circuit
- Patheon Reports Fourth Quarter and Full Fiscal 2012 Results
- Ironwood and Forest Announce U.S. Availability of Linzess (Linaclotide)
- Lundbeck to Divest a Portfolio of Non-core Products as Part of its Strategy to Focus on Newer, Strategic CNS-products
- Sun Pharma Acquires URL Generic Business from Takeda
- Teva Enters Agreement with Handok to Establish Business Venture with Significant Presence in Korean Pharmaceutical Market
- NICE Issues Good Practice Guidance for Local Formularies
- Eisai Inc. Divests U.S. Rights for GLIADEL Wafer (polifeprosan 20 with carmustine implant) to Arbor Pharmaceuticals
- BRILINTA (Ticagrelor) Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of STEMI Patients
- FDA Drug Safety Communication: Warning Against Use of Xyrem (sodium oxybate) with Alcohol or Drugs Causing Respiratory Depression
December 18, 2012
- Eisai Disagrees with German Institute for Quality and Efficiency in Health Care (IQWiG) Report on Innovative Antiepileptic Drug Fycompa (Perampanel) for the Treatment of Partial Epilepsy
- NICE Draft Guidance Does Not Recommend Bevacizumab as Advanced Ovarian Cancer Treatment
- Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics
- Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program
- Transparency in Clinical Trials: A New Paradigm Shift?
December 19, 2012
- Amgen Takes Third License for Rights to Use ImmunoGen's TAP Technology
- Lundbeck Invests Significantly in Product Development and Product Launches and has Consequently Revised its Financial Plans
- PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva's Hlovovec Production Facility to Wood Pharma Holding
- NICE Says Yes in Draft Guidance to Eltrombopag for the Treatment of Chronic Immune (idiopathic) Thrombocytopenic Purpura
- New Drug Discovery Company NeRRe Therapeutics Created to Develop Neurokinin Antagonists from GSK
- GlycoVaxyn AG Announces Strategic Collaboration with GSK to Develop New Bacterial Vaccines using GlycoVaxyn's Bio-Conjugation Technology
- Amgen Finalizes Agreement Resolving Previously Announced Federal Investigations
December 20, 2012
- Boehringer Ingelheim Pharmaceuticals, Inc. Announces Updated Safety Information for Pradaxa (dabigatran etexilate mesylate) Related to Prosthetic Heart Valves
- Vertex Announces Update to U.S. Prescribing Information for Incivek (telaprevir)
- Allergan, Inc. Announces Completion of SkinMedica, Inc. Acquisition
- Orion and Mylan settle patent dispute over the proprietary drug Comtan
- Biogen Idec Forms First-of-Its-Kind Research Consortium to Identify ALS Drug Targets
- Amicus Treatment for Fabry Disease Fails in Study
- Comedian Jerry Seinfeld Kicks Off The Stand Up for a Cure 2013 Concert Series With New York Show at The Theater at MSG
- Acadia Pharmaceuticals to Receive Funding from Fast Forward and EMD Serono for Multiple Sclerosis Program
- Sanofi US Agrees to Pay $109 Million to Resolve False Claims Act Allegations of Free Product Kickbacks to Physicians
- COLUMN: Jobs, Jobs, Jobs and More Jobs
- Vivus Announces Express Scripts Adds Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV To Its Standard Benefits Program
- Dendreon Sells New Jersey Immunotherapy Manufacturing Facility
December 21, 2012
- Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
- Elan Announces Completion of Demerger of Prothena Corporation plc
- Halozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And Commercialize Subcutaneous Biologics Using Recombinant Human Hyaluronidase
- Endo Pharmaceutals Fails in Maneuver to Have Own Drug Called Unsafe
- Eli Lilly Pays $29M to Settle SEC Corruption Probe
- FDA Approves Gattex (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome
- Roche and PSS Sign Agreement to Develop a Fully Automated Workflow Solution for Next-generation Sequencing Platforms
December 27, 2012
- Takeda Announces Mutual Termination of Amylin / Takeda Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
- Bristol-Myers, Pfizer's Eliquis Approved in Japan
- FDA Approves Aegerion Cholesterol Disorder Drug
- FDA Approves Tamiflu for Children 2 Weeks and Up
December 28, 2012
- Court Ruling Could Grant Latitude on Drug Claims
- Omeros Misses Target in Clinical Trial
- Teva Cancels Proteologics Collaboration
- Victory Pharma Inc. of San Diego Pays $11.4 Million to Resolve Kickback Allegations in Connection with Promotion of Its Drugs
- Signing a License Agreement and A Joint Research Agreement for New Anti-Cancer Drug Candidate Compounds Targeting the Ras Signaling Pathway
- Watson Confirms Velcade Patent Challenge
- Perrigo Company Acquires Remaining Stake In Cobrek Pharmaceuticals, Inc. For Approximately $45 Million
- K-V Pharmaceutical Receives Court Approval of Hologic Settlement
